D rug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight loss results comparable to those of popular GLP-1 injectables like ...

Rival companies trying to develop oral weight-loss candidates include Novo Nordisk, which has an oral formulation of ...

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a ...

The early data from UBT251 suggests it may be as similarly fast-acting as another of Novo Nordisk’s obesity hopefuls, the oral GLP-1 and amylin receptor amycretin, which showed 13.1% weight loss ...

Until 24 March, Novo Nordisk also claimed the throne as Europe ... adding that even if CagriSema is a commercial failure, the firm’s amycretin program (that could enter phase 3 this year ...

Novo Nordisk NVO shares have lost 15.2% so far ... In January, the company reported that patients receiving the highest dose of amycretin experienced a 22% weight loss compared with a gain in ...